Figure 3

4-OI reduced oxaliplatin-associated and lobaplatin-associated ROS production. (A–D) Compared with the application of oxaliplatin or lobaplatin alone, 4-OI combined with oxaliplatin or lobaplatin significantly reduced the ROS production by flow cytometry. Data are shown as the mean ± SD, *p < 0.05; **p < 0.01; ***p < 0.001.